Last reviewed 2026-05-25 · How we verify

RYZNEUTA (EFBEMALENOGRASTIM ALFA-VUXW)

EVIVE BIOTECHNOLOGY · FDA-approved approved Under review Quality 10/100

RYZNEUTA (generic name: EFBEMALENOGRASTIM ALFA-VUXW) is a Leukocyte Growth Factor [EPC] drug developed by EVIVE BIOTECHNOLOGY. It is currently FDA-approved.

Efbemalenograstim alfa-vuxw binds to specific cell surface receptors on hematopoietic cells, stimulating their proliferation, differentiation, and functional activation.

RYZNEUTA is a protein that acts as an agonist to the Granulocyte colony-stimulating factor receptor. It is classified as a drug that stimulates this receptor, which is involved in the production of granulocytes.

At a glance

Generic name	EFBEMALENOGRASTIM ALFA-VUXW
Sponsor	EVIVE BIOTECHNOLOGY
Drug class	Leukocyte Growth Factor [EPC]
Target	specific cell surface receptors
Therapeutic area	Other
Phase	FDA-approved

Mechanism of action

Efbemalenograstim alfa-vuxw is a colony-stimulating factor that works by binding to specific receptors on the surface of hematopoietic cells. This binding stimulates the cells to proliferate, differentiate, and become functionally active.

Approved indications

No approved indications tracked.

Common side effects

Nausea
Anemia
Thrombocytopenia
Fatigue
Bone pain

Serious adverse events

Splenic Rupture
Acute Respiratory Distress Syndrome
Serious Allergic Reactions
Sickle Cell Crisis in Patients with Sickle Cell Disorders
Glomerulonephritis
Leukocytosis
Capillary Leak Syndrome
Myelodysplastic Syndrome (MDS) and Acute Myeloid Leukemia (AML)
Aortitis

Key clinical trials

A Multicenter, Exploratory Clinical Study of Efbemalenograstim Alfa-vuxw Injection for Primary/Secondary Prevention in Patients With Solid Tumors at High Risk for Febrile Neutropenia (FN) or Intermedi (Phase 2)

Primary sources

Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.

Source	Used for
ClinicalTrials.gov	Trial enrolment, design, endpoints, results

Competitive intelligence

For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:

RYZNEUTA CI brief — competitive landscape report
RYZNEUTA updates RSS · CI watch RSS
EVIVE BIOTECHNOLOGY portfolio CI

Frequently asked questions about RYZNEUTA

What is RYZNEUTA?

RYZNEUTA (EFBEMALENOGRASTIM ALFA-VUXW) is a Leukocyte Growth Factor [EPC] drug developed by EVIVE BIOTECHNOLOGY.

How does RYZNEUTA work?

Efbemalenograstim alfa-vuxw binds to specific cell surface receptors on hematopoietic cells, stimulating their proliferation, differentiation, and functional activation.

Who makes RYZNEUTA?

RYZNEUTA is developed and marketed by EVIVE BIOTECHNOLOGY (see full EVIVE BIOTECHNOLOGY pipeline at /company/evive-biotechnology).

What is the generic name of RYZNEUTA?

EFBEMALENOGRASTIM ALFA-VUXW is the generic (nonproprietary) name of RYZNEUTA.

What drug class is RYZNEUTA in?

RYZNEUTA belongs to the Leukocyte Growth Factor [EPC] class. See all Leukocyte Growth Factor [EPC] drugs at /class/leukocyte-growth-factor-epc.

What development phase is RYZNEUTA in?

RYZNEUTA is FDA-approved (marketed).

What are the side effects of RYZNEUTA?

Common side effects of RYZNEUTA include Nausea, Anemia, Thrombocytopenia, Fatigue, Bone pain. Serious adverse events: Splenic Rupture, Acute Respiratory Distress Syndrome, Serious Allergic Reactions, Sickle Cell Crisis in Patients with Sickle Cell Disorders.

What does RYZNEUTA target?

RYZNEUTA targets specific cell surface receptors and is a Leukocyte Growth Factor [EPC].

Drug class: All Leukocyte Growth Factor [EPC] drugs
Target: All drugs targeting specific cell surface receptors
Manufacturer: EVIVE BIOTECHNOLOGY — full pipeline
Therapeutic area: All drugs in Other

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing